Is the FDA contributing to the homelessness crisis?
The Hill
The FDA’s REMS program has been found to have unintentionally created barriers to accessing clozapine, a crucial antipsychotic drug for treatment-resistant schizophrenia, leading to tragic stories of relapses and suicide attempts.
